111 related articles for article (PubMed ID: 28244463)
21. Outpatient weekly 24-hour infusional adjuvant chemotherapy of cisplatin, 5-fluorouracil, and leucovorin for high-risk nasopharyngeal carcinoma.
Lin JC; Jan JS; Chen KY; Hsu CY; Liang WM; Wang WY
Head Neck; 2003 Jun; 25(6):438-50. PubMed ID: 12784235
[TBL] [Abstract][Full Text] [Related]
22. The prognostic influence of prevertebral space involvement in nasopharyngeal carcinoma.
Lee CC; Chu ST; Chou P; Lee CC; Chen LF
Clin Otolaryngol; 2008 Oct; 33(5):442-9. PubMed ID: 18983377
[TBL] [Abstract][Full Text] [Related]
23. A concurrent chemoirradiation with cisplatin followed by adjuvant chemotherapy with ifosfamide, 5-fluorouracil, and leucovorin for stage IV nasopharyngeal carcinoma.
Chua DT; Sham JS; Au GK
Head Neck; 2004 Feb; 26(2):118-26. PubMed ID: 14762880
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of docetaxel, cisplatin, and 5-FU induction chemotherapy followed by chemoradiotherapy in locoregionally advanced nasopharyngeal cancer.
Bae WK; Hwang JE; Shim HJ; Cho SH; Lee JK; Lim SC; Chung WK; Chung IJ
Cancer Chemother Pharmacol; 2010 Feb; 65(3):589-95. PubMed ID: 19830427
[TBL] [Abstract][Full Text] [Related]
25. Matched analysis of induction chemotherapy plus chemoradiotherapy versus induction chemotherapy plus radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a multicenter study.
Zhang B; Hu Y; Xiong RH; Pan YF; Xu QL; Kong XY; Cai R; Chen QQ; Tang HY; Jiang W
Oncotarget; 2017 Feb; 8(8):14078-14088. PubMed ID: 27845907
[TBL] [Abstract][Full Text] [Related]
26. Non-endemic locoregionally advanced nasopharyngeal carcinoma: long-term outcome after induction plus concurrent chemoradiotherapy in everyday clinical practice.
Boscolo-Rizzo P; Tirelli G; Mantovani M; Baggio V; Lupato V; Spinato G; Gava A; Da Mosto MC
Eur Arch Otorhinolaryngol; 2015 Nov; 272(11):3491-8. PubMed ID: 25367705
[TBL] [Abstract][Full Text] [Related]
27. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Chen L; Hu CS; Chen XZ; Hu GQ; Cheng ZB; Sun Y; Li WX; Chen YY; Xie FY; Liang SB; Chen Y; Xu TT; Li B; Long GX; Wang SY; Zheng BM; Guo Y; Sun Y; Mao YP; Tang LL; Chen YM; Liu MZ; Ma J
Lancet Oncol; 2012 Feb; 13(2):163-71. PubMed ID: 22154591
[TBL] [Abstract][Full Text] [Related]
28. Chemoradiotherapy with weekly low-dose docetaxel and cisplatin concurrent with radiation for patients with locally advanced nasopharyngeal carcinoma, followed by adjuvant chemotherapy for selected patients.
Nakahara S; Hanamoto A; Seo Y; Miyaguchi S; Yamamoto Y; Tomiyama Y; Yoshii T; Takenaka Y; Yoshioka Y; Isohashi F; Ogawa K; Inohara H
Jpn J Clin Oncol; 2016 Oct; 46(10):903-910. PubMed ID: 27474126
[TBL] [Abstract][Full Text] [Related]
29. Concurrent Chemoradiotherapy with Docetaxel, Cisplatin and 5-Fluorouracil (TPF) in Patients with Nasopharyngeal Carcinoma.
Komatsu M; Arai Y; Yabuki K; Sano D; Shiono O; Sakuma Y; Nishimura G; Takahashi M; Taguchi T; Oridate N
Anticancer Res; 2015 Dec; 35(12):6861-7. PubMed ID: 26637908
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and feasibility of cisplatin-based concurrent chemoradiotherapy for nasopharyngeal carcinoma.
Demizu Y; Sasaki R; Soejima T; Maruta T; Okamoto Y; Yamada K; Yoden E; Ejima Y; Ota Y; Ishida H; Nibu K; Sugimura K
Jpn J Clin Oncol; 2006 Oct; 36(10):620-5. PubMed ID: 16905756
[TBL] [Abstract][Full Text] [Related]
31. Treatment of Childhood Nasopharyngeal Carcinoma With Induction Chemotherapy and Concurrent Chemoradiotherapy: Results of the Children's Oncology Group ARAR0331 Study.
Rodriguez-Galindo C; Krailo MD; Krasin MJ; Huang L; McCarville MB; Hicks J; Pashankar F; Pappo AS
J Clin Oncol; 2019 Dec; 37(35):3369-3376. PubMed ID: 31553639
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Long-term results of a phase 3 multicentre randomised controlled trial.
Chen L; Hu CS; Chen XZ; Hu GQ; Cheng ZB; Sun Y; Li WX; Chen YY; Xie FY; Liang SB; Chen Y; Xu TT; Li B; Long GX; Wang SY; Zheng BM; Guo Y; Sun Y; Mao YP; Tang LL; Chen YM; Liu MZ; Ma J
Eur J Cancer; 2017 Apr; 75():150-158. PubMed ID: 28235726
[TBL] [Abstract][Full Text] [Related]
33. The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma.
Liu LT; Tang LQ; Chen QY; Zhang L; Guo SS; Guo L; Mo HY; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):862-9. PubMed ID: 26530755
[TBL] [Abstract][Full Text] [Related]
34. Phase II trial of neoadjuvant docetaxel and cisplatin followed by intensity-modulated radiotherapy with concurrent cisplatin in locally advanced nasopharyngeal carcinoma.
Zhong YH; Dai J; Wang XY; Xie CH; Chen G; Zeng L; Zhou YF
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1577-83. PubMed ID: 23549883
[TBL] [Abstract][Full Text] [Related]
35. Results of combined modality treatment for nasopharyngeal cancer.
Venkitaraman R; Ramanan SG; Vasanthan A; Sagar TG
J Cancer Res Ther; 2009; 5(2):102-6. PubMed ID: 19542665
[TBL] [Abstract][Full Text] [Related]
36. A multicenter, phase 3, randomized trial of concurrent chemoradiotherapy plus adjuvant chemotherapy versus radiotherapy alone in patients with regionally advanced nasopharyngeal carcinoma: 10-year outcomes for efficacy and toxicity.
Lee AWM; Tung SY; Ng WT; Lee V; Ngan RKC; Choi HCW; Chan LLK; Siu LL; Ng AWY; Leung TW; Yiu HHY; O'Sullivan B; Chappell R
Cancer; 2017 Nov; 123(21):4147-4157. PubMed ID: 28662313
[TBL] [Abstract][Full Text] [Related]
37. Progress report of a randomized trial comparing long-term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage III to IVB nasopharyngeal carcinoma from endemic regions of China.
Chen Y; Sun Y; Liang SB; Zong JF; Li WF; Chen M; Chen L; Mao YP; Tang LL; Guo Y; Lin AH; Liu MZ; Ma J
Cancer; 2013 Jun; 119(12):2230-8. PubMed ID: 23576020
[TBL] [Abstract][Full Text] [Related]
38. Propensity score matching analysis of cisplatin-based concurrent chemotherapy in low risk nasopharyngeal carcinoma in the intensity-modulated radiotherapy era.
Zhang LN; Gao YH; Lan XW; Tang J; Su Z; Ma J; Deng W; OuYang PY; Xie FY
Oncotarget; 2015 Dec; 6(41):44019-29. PubMed ID: 26528755
[TBL] [Abstract][Full Text] [Related]
39. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival.
Lin JC; Jan JS; Hsu CY; Liang WM; Jiang RS; Wang WY
J Clin Oncol; 2003 Feb; 21(4):631-7. PubMed ID: 12586799
[TBL] [Abstract][Full Text] [Related]
40. A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma.
Chan AT; Teo PM; Leung TW; Leung SF; Lee WY; Yeo W; Choi PH; Johnson PJ
Int J Radiat Oncol Biol Phys; 1995 Oct; 33(3):569-77. PubMed ID: 7558945
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]